RE:RE:RE:RE:RE:Trend is your friend
Not a subscriber so can't copy but I read the article and it points out yet again what we already know. Hydropothecary is undervalued. Targets are 72% above current share price . Wait until the uplisting. We'll be pi$$ing in the tall grass with the big dogs.